Authors
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
A Pathologist’s Crucial Role in Diagnosing Breast CancerA pathologist is often needed to definitively diagnose a patient with cancer based on the tissue testing results.
Latest:
HER2+ Advanced Breast Cancer: Selecting Third-Line TherapySara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.
Latest:
Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory ArthritisThis case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.
Latest:
Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant CyclophosphamideThis article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.
Latest:
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing PracticeRegistered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
How do PDX and Computational Models Assist in the Development of ADCs?Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
Latest:
Key Takeaways from the PARADIGM StudyDrs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Trevor J. Pugh, PhD, on Reducing the Burden of Serial Testing for MMRd With 1 Sequencing ProtocolCancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case ReportHans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Relapsed/Refractory CLL: Key Takeaways and Ongoing ChallengesClosing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLCData from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.
Latest:
CLL Workshop Emphasizes Engaging Conversations on Shared Treatment PlanningBoth clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
